Low-dose imipramine for treatment of indigestion
Functional dyspepsia, also known as indigestion, is a clinical problem of considerable magnitude for the health-care system due to its high prevalence, the chronic relapsing nature of symptoms, and the lack of effective treatments. The study on “Low-dose imipramine for refractory functional dyspepsia: a randomised, double-blind, placebo-controlled trial” shows that imipramine, a tricyclic antidepressant, should be considered in all patients with functional dyspepsia who have failed first-line medical therapies, particularly in those with coexistent mood disorder (Lancet Gastroenterol Hepatol. 2018 Dec;3(12):837-844. doi: 10.1016/S2468-1253(18)30303-0. Epub 2018 Oct 22).
Anyone interested in future collaboration in this field of research is welcome to contact our key investigator, Prof Justin Wu of our Department of Medicine and Therapeutics. Prof Wu is an expert in gastroesophageal reflux disease and functional gastrointestinal disorder; he has published over 190 peer-reviewed articles, including first-authored publications in top-ranked journals such as Gastroenterology and Gut.
Read the full artcile: https://www.sciencedirect.com/science/article/pii/S2468125318303030?via%3Dihub
More about research at CU Medicine: https://research.med.cuhk.edu.hk